BPC-157 / TB-500 Blend — Research Product Overview

**Disclaimer:** This product overview is provided strictly for in-vitro and preclinical research use. The [BPC-157](/catalog/bpc-157) / [TB-500](/catalog/tb-500) blend is not approved by the FDA for human use, is not a drug, food, or cosmetic, and nothing in this document constitutes medical advice or a recommendation for human administration. Materials are sold to qualified research professionals for laboratory investigation only.

Overview

The BPC-157 / TB-500 blend is a stacked formulation marketed for tissue-repair research that combines two of the most extensively studied regenerative peptides into a single lyophilized product. The rationale for co-formulation is the partially non-overlapping mechanisms of the two peptides: BPC-157 acts predominantly through the FAK-paxillin axis, nitric-oxide modulation, and VEGF-mediated angiogenesis, while thymosin beta-4 (TB-500) acts primarily through G-actin sequestration and ILK/Akt-driven cell migration with strong anti-inflammatory and progenitor-reactivation effects. Researchers studying complex injury models — where matrix remodeling, vascularization, cell migration, and inflammation must be addressed simultaneously — have published comparative work using each peptide alone and in combination.

For mechanism-of-action depth on each component see BPC-157 mechanisms, the BPC-157 vs TB-500 comparison, and the dedicated single-peptide overviews — Product overview: BPC-157 and Product overview: TB-500.

Composition

A typical research blend supplies the two peptides at a 1:1 mass ratio, although other ratios (2:1 BPC:TB, or 1:2) are available on request. Each lot is supplied with separate purity assessments for each component.

• Component A: BPC-157 (15 aa, MW 1419.53 Da)

- Sequence: GEPPPGKPADDAGLV

• Component B: TB-500 / Thymosin beta-4 (43 aa, MW ~4963 Da acetylated)

- Sequence: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES

• Typical fill: 5 mg BPC-157 + 5 mg TB-500 per vial (10 mg total peptide content)

Because the molecular weights differ by roughly 3.5×, a 1:1 mass blend corresponds to roughly 3.5:1 molar excess of BPC-157 over TB-500. Researchers should account for this when designing dose-response studies; mass-equivalent comparisons between blend and single-component arms can produce misleading interpretations.

Mechanistic Rationale (Summary)

The two peptides are pharmacologically complementary rather than redundant:

| Process | BPC-157 | TB-500 (Tβ4) |

|---|---|---|

| Cell migration | FAK-paxillin | ILK / Akt |

| Angiogenesis | VEGF / VEGFR2 | VEGF + MMP, endothelial progenitor mobilization |

| Anti-inflammation | NO normalization, neutrophil suppression | NF-κB suppression |

| Stem/progenitor effects | Satellite cell activation | Epicardial progenitor reactivation |

| Stability | Stable in gastric acid | Native acetylation, intracellular abundance |

Because no head-to-head molecular target study has demonstrated true synergy at the receptor level (no high-affinity receptor for either peptide has been identified), the blend's rationale rests on additive coverage of repair-relevant processes rather than on a defined synergistic pharmacology.

Preclinical Context

Most of the published evidence in this area concerns the two peptides studied independently. Comparative work — for example, in the Sikiric laboratory's cross-model surveys — has often used both peptides as separately administered arms rather than as co-formulated blends. As of early 2026, no peer-reviewed clinical trial of a fixed-ratio BPC-157/TB-500 combination has been published. Researchers should regard the blend as an experimental research-use article whose pharmacokinetics, isobolographic profile, and dose-response surface remain to be characterized.

Comparator Peptides and Molecules

The closest mechanistic comparator to a BPC/TB blend is a sequential single-peptide protocol applied to the same injury model. Researchers have asked whether a 1:1 mass blend produces effects that cannot be reproduced by sequential or staggered administration — to date, no isobolographic or fixed-ratio dose-response study has answered this question definitively. Other regenerative blends or adjuncts that researchers may consider as comparators include GHK-Cu, which adds copper-dependent matrix remodeling; the KLOW blend, which combines four regenerative peptides for veterinary tissue-repair research; and senolytic-repair pairings using FOXO4-DRI to clear injury-induced senescent cells before repair-peptide administration. NAD+ precursor co-treatment via NAD vs NMN vs NR is a less-validated but mechanistically plausible adjunct in aged-animal injury studies. The growth-hormone axis intersects both component peptides through different routes — BPC-157 via GHR upregulation in tendon fibroblasts, and TB-500 via ILK/Akt-driven survival signaling that overlaps growth-factor pathways.

Deeper Preclinical Breakdown

Three categories of preclinical studies inform blend rationale, even when the combination itself was not directly tested. Sikiric's 2018 review (PMID 29886805) catalogues parallel results in BPC-157 and Tβ4 studies of muscle, tendon, and gut repair, showing largely additive coverage of repair-relevant endpoints when each peptide is studied separately in equivalent models. Bock-Marquette et al. 2004 (PMID 15378064) demonstrated that intracardiac Tβ4 alone (400 µg + 150 µg IP every other day) significantly improved post-MI ejection fraction; mechanistic dissection identified ILK as the proximal kinase. A separate body of BPC-157 cardioprotection work (Sikiric group, multiple papers 2014–2020) demonstrated reduced arrhythmia and infarct size at 10 µg/kg IP. Neither group has published a head-to-head blend versus monotherapy comparison in this model.

Chang et al. 2011 (PMID 21172366) on BPC-157 FAK/paxillin activation in tendon fibroblasts and Malinda et al. 1999 (PMID 10587401) on Tβ4 dermal wound healing in aged mice are the two most-cited mechanistic anchors. The blend's design rationale hinges on the assumption that simultaneously activating FAK-paxillin migration, ILK/Akt survival, VEGF-driven angiogenesis, and NF-κB suppression is preferable to sequential activation. This assumption is plausible but unproven. Researchers running blend studies should always include single-peptide control arms and document the molar imbalance: a 1:1 mass blend of 5 mg + 5 mg corresponds to roughly 3.5 µmol BPC-157 versus 1.0 µmol Tβ4, a ~3.5× molar excess of the smaller peptide.

Formulation Considerations

Blends are typically supplied as a 10 mg total lyophilized fill (5 mg BPC-157 + 5 mg Tβ4) co-lyophilized from a homogeneous solution to ensure component uniformity across the cake. Reconstitution with bacteriostatic water for injection is standard. Because TB-500 dictates the gentler handling profile (acid-sensitive backbone, more freeze-thaw labile), the entire blend should be treated under TB-500 storage rules. Common impurities visible on a quality COA include separately reported des-amido BPC-157, des-acetyl Tβ4, oxidized methionine variants of Tβ4, and truncation fragments of either component. The peptide reconstitution guide and peptide solubility guide cover general protocol; the peptide storage stability reference covers freeze-thaw mitigations specific to long peptides like Tβ4. Researchers reading COAs should verify both component identities by mass spectrometry — see how to read a peptide COA.

Research-Context Dosing Ranges

Because no peer-reviewed blend dose-response study exists, researchers default to component-specific doses applied through the same vehicle. Rodent studies have used IP doses of 10 µg/kg BPC-157 + 6–16 mg/kg Tβ4, recognizing the molar mismatch. In-vitro studies have used 100 nM to 10 µM BPC-157 + 100 ng/mL to 10 µg/mL Tβ4. Veterinary tendon-repair studies in horses have used parenteral doses on the order of 2 mg of each peptide weekly. No human dosing is implied or recommended; both peptides appear on the WADA prohibited list 2026.

Common Research Applications

• In-vitro screening of combined repair signals (FAK + ILK pathway co-activation)
• Rodent crush-injury and tendon-transection models where vascular, cellular, and matrix processes must be addressed simultaneously
• Comparative arms in study designs that include single-peptide controls
• Senescence-context tissue-repair studies (often paired with FOXO4-DRI clearance arms)

Handling, Reconstitution, and Storage

• Form supplied: white lyophilized co-blend, typically 10 mg total per vial
• Reconstitution: bacteriostatic water for injection or sterile water at the desired final volume; full-length TB-500 dictates the gentler handling profile
• Working concentration: 1–2 mg/mL combined typical for in-vitro work
• Lyophilized stability: ≥24 months at -20 °C
• Reconstituted stability: up to 7–10 days at 2–8 °C; freeze aliquots at -20 °C / -80 °C; avoid freeze-thaw
• Avoid: harsh acidic reconstitution buffers — TB-500 is more sensitive to acid hydrolysis than BPC-157

See peptide reconstitution guide and peptide storage stability.

Lab Specifications

• [HPLC](/research/glossary#hplc) purity target: each component ≥98.0% by RP-HPLC at 220 nm prior to blending
• Identity confirmation: dual ESI-MS / MALDI-TOF, observed masses within ±1 Da (BPC-157) and ±2 Da (TB-500) of theoretical
• Component ratio: verified by integrated HPLC peak area; reported on COA
• Endotoxin: <1 EU/mg for cell-culture grade
• Residual solvents: within ICH Q3C limits

For COA interpretation see how to read a peptide COA.

Cross-References

Related Viking Labs research:

• Product overview: BPC-157
• Product overview: TB-500
• BPC-157 vs TB-500 comparison
• Product overview: KLOW blend
• Product overview: GHK-Cu
• Peptide drug delivery 2026

Summary

The BPC-157 / TB-500 blend offers researchers a single-vial format for studies where combined coverage of cell migration, angiogenesis, inflammation, and matrix remodeling is desired. The mechanistic rationale is additive rather than synergistic in the strict pharmacological sense, and the literature on fixed-ratio blends remains thinner than the literature on each peptide alone. Researchers should design experiments with single-peptide control arms and account for the molar imbalance inherent in 1:1 mass blends.

*This document is provided for research and educational purposes only. Viking Labs does not sell products intended for human consumption.*